An observational study in Acute Myeloid Leukemia, sponsored by Ciceri Fabio. Recruiting at 2 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-08.
Sponsored by Ciceri Fabio · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 229 studies in Leukemia, Myeloid, Acute with a site in Italy — 45 open to participants now, 67 under way, 16 of them phase 3. Leukemia, Myeloid, Acute · Italy.
Among the 229 studies in Leukemia, Myeloid, Acute with a site in Italy, this one is the 21st largest by planned enrollment of the 31 observational ones that give a count, is one of 11 that started in 2025, is one of 31 observational ones, reaches primary completion later than 21 of the 66 other live ones, and was the 197th registered.
3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →45 of the 229 studies in Leukemia, Myeloid, Acute with a site in Italy are open now. Recruiting first, the newest first:
Gruppo Italiano Malattie EMatologiche dell'Adulto · Sites in Italy
Ages 18–75 · Healthy volunteers
Fondazione Matilde Tettamanti Menotti De Marchi Onlus · Sites in Italy
Ages 6 mo–75 yrs
Gruppo Italiano Malattie EMatologiche dell'Adulto · Sites in Italy
Ages 18+
AbbVie · Sites in Italy, United States, Australia and 4 more countries
Ages 6 mo–17 yrs
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · Sites in Italy
Ages 18–75
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
229 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 68 · Phase 2 100 · Phase 3 62 · Phase 4 1
First in 1993; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is below the median of 114 across 395 observational studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 120 across the 196 interventional studies, 202 across the 31 observational. Of the 140 that completed or were terminated, 77 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
130 of 229 have an industry lead sponsor. The 10 most frequent:
Ciceri Fabio is the lead sponsor of 8 studies on the registry; 6 are open to participants now.
Ciceri Fabio has 3 studies filed under Leukemia, Myeloid, Acute — fewer than ten, so there is no comparison to draw.
14 of the studies in Leukemia, Myeloid, Acute with a site in Italy that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05183035Phase 3PedAL BCU, LLCVenetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | 2027-02 |
| NCT05429632Phase 3Priothera SASMocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT | 2027-05 |
| NCT05907057Phase 3Servier Affaires MédicalesAn Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy. | 2027-10-15 |
| NCT04256317Phase 3Taiho Oncology, Inc.A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | 2027-11-01 |
| NCT04232241Universitätsklinikum Hamburg-EppendorfMatched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia | 2026-11-22 |
Add all 14 to your calendar (.ics) → With an account.
Among the 229 studies in Leukemia, Myeloid, Acute with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is designed as a collection of biological samples of newly diagnosed acute myeloid leukemia (AML) patients treated in the clinical units involved. Samples of peripheral blood (PB) and bone marrow (BM) will be analyzed to determine the Inflammasome profile before and after a first-line chemotherapy treatment.
Acute myeloid leukemia (AML) is a highly aggressive and unfavorable malignancy primarily affecting bone marrow (BM) myeloid cells, particularly in older individuals. The standard treatment for fit, intermediate and high-risk patients involves chemotherapy followed by allogeneic hematopoietic stem cell transplantation (HSCT). However, around 60% of patients experience relapse, requiring second-line therapies that offer a reduced likelihood of achieving a permanent cure.
Inflammation significantly influences AML development, progression, leukemic cell behavior, and treatment response. Interactions between leukemic cells and microenvironment promote their growth, survival, and drug resistance. The inflammasome, an intracellular complex crucial for promoting inflammation, triggers the release of the proinflammatory cytokines interleukin (IL)-1beta and IL-18, and induces pyroptosis (inflammatory cell death) in response to inflammatory stimuli. There is growing evidence suggesting a link between the inflammasome and AML, with components of the inflammasome being overexpressed in leukemic cells. The precise mechanisms by which the inflammasome and its activation pathways influence AML still need to be fully understood.
We speculate that excessive inflammasome activity in AML disrupts the balance of cytokine production, leading to chronic inflammation, which interferes with the normal development and function of hematopoietic cells in the BM microenvironment. This heightened inflammasome signature could impact the way patients respond to chemotherapy, potentially altering inflammatory processes, ultimately reducing the efficacy of the treatment. Variations in inflammasome activation among AML patients may explain differences in treatment outcomes, including response rates, hematopoietic recovery, remission duration, and overall survival.
Understanding the molecular mechanisms involved in AML, particularly the role of the inflammasome, could allow a better disease risk stratification and the development of potential targeted therapies and interventions, which could improve treatment outcomes. More specifically, identifying potential therapeutic targets within the inflammasome pathway, may drive to the design of new treatment strategies, precisely aimed at correcting inflammasome dysregulation in AML. From the clinical point of view, these insights could assist healthcare professionals in taking informed decisions in the management of AML patients. By modulating inflammasome activity or targeting specific pathway components, we could develop personalized treatment approaches tailored to individual patient needs, optimizing treatment response and possibly minimizing chemotherapy-related side effects. This personalized approach has the potential to enhance the quality of life for patients, reduce complications, and increase the overall effectiveness of treatments.
During the Study period patients referring to the clinical centers will undergo the standard diagnostic and therapeutic process for their pathology, according to international guidelines. For all the patients that will agree to participate, clinical data and biological samples will be analyzed for the aims of the Study. The retrospective part of the data and material collection must have bio-banked material in compliance with the ethics and regulatory standards for the research purpose.
Due to the Observational nature of the Study, all diagnostic procedures and treatments applied are considered common practice. All treatments comply with the ATC Code L01, the different schemes of treatment could be categorized under an "intensive" or "non intensive" protocol.
Commonly used intensive induction regimens are:
Non intensive induction and consolidation schemes include: azaticidine (75 mg/m\^2) day 1-7 + Venetoclax at variable dose.
For the retrospective collection of samples, the preceding version of ELN guidelines (2017) will be appliedThe main hypothesis of the study is that an excessive inflammasome activity in AML disrupts the balance of cytokine production, leading to a clinically relevant inflammatory state, which interferes with the response to chemotherapy.
In two years, we plan to recruit 80 adult participants with a new diagnosis of AML undergoing first line chemotherapy treatment.
The protocol is a multicenter, national, observational study; indeed, it is based on the Clinical Practice and is aimed at gathering information from the biological samples collected during the diagnosis process and after a first line treatment. The Study will be prospective and retrospective. The total duration of enrolment will be from August 2024 to January 2026, the observation period will be up to 6 months. The information about the treatment and the assessment on disease response/relapse/progression will be collected for stratification and monitoring purpose. Retrospectively, specimens, demographical and clinical information are retrieved from AML patients previously recruited by UO1 will be utilized. Prospectively, new AML patients will be recruited. UO1 recruits AML patients, collects biological samples at diagnosis and after chemotherapy, processes, and biobanks specimens, and conducts functional inflammasome assays, gene expression analysis, and immunophenotyping of AML blasts in peripheral blood and bone marrow. Additionally, immunohistochemistry is performed on bone marrow biopsies. UO2 recruits AML patients, processes and cryobank specimens, and ships samples to UO1. It also produce all diagnostic data for clinical standard of AML blasts in peripheral blood and bone marrow, with immunohistochemistry conducted on bone marrow biopsies.
The biological samples collected for the study include bone marrow, biopsies, and peripheral blood.
The study will be conducted on the population seen at the clinical centers as per common practice. The subjects eligible will be identified during the clinical practice diagnostic process for AML.
The study will involve a total of 80 subjects based on the statistical design for the Study. The Coordinating Unit of the Study will include at least 55 subjects, the Other cooperating Centers will provide the remaining subjects.
The retrospective samples will be identified through Biobanking Records in the pool of samples stocked and we estimate around 25% of the total population included (\~20 subjects).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For the retrospective population we will select:
biological samples (BM , BM Aspirates and PB) already banked upon research purpose informed consent and collected from the 01/06/2006 up to 01/06/2024 from adults patients with diagnosis of acute myeloid leukemia according to ELN2017 Criteria.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
acute myeloid leukemia (AML) patients treated in the clinical units
Other: Clinical Practice
All the procedures in Study will be conducted as per Clinical practice for the pathology and all the samples will be collected according to ELN guidelines. There are no additional procedures but will be additionally collected up 20ml of peripheral blood and up to 15ml of Bone Marrow Aspirate at the same time of clinically indicated diagnostic procedures.
Inflammasome Activity
The outcome variable is the inflammasome activation in AML blasts (PB e BM)
Time frame: At diagnosis, in case of treatment failure and at 6 months after first line chemotherapy initiation
Correlation Inflammasome and Therapy
To evaluate the correlation between inflammasome activity and response to chemotherapy in patients with AML
Time frame: At diagnosis, in case of treatment failure and at 6 months after first line chemotherapy initiation
Plan to share: No — all Data that underlie results will be published on a peer reviewed paper as for legal requirments
No publications or documents are linked to this record.
Ran from Feb 2025 to primary completion in May 2026, 14 months.
Of 128 non-industry observational studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 234. This study's 14 months is below that.
Counting every sponsor, half of 160 studies reached it within 54 months; a quarter within 35 and three quarters within 154.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ciceri Fabio